Nivalis Therapeutics Inc. (NASDAQ:NVLS) was downgraded by equities researchers at Raymond James Financial Inc. from an “outperform” rating to a “market perform” rating in a report issued on Tuesday.

Other equities research analysts also recently issued research reports about the company. Cowen and Company downgraded Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. Robert W. Baird downgraded Nivalis Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $29.00 to $3.00 in a report on Tuesday. Stifel Nicolaus downgraded Nivalis Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $16.00 to $3.25 in a report on Tuesday. Zacks Investment Research upgraded Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Saturday, November 5th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nivalis Therapeutics in a report on Monday, August 8th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $9.60.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:NVLS)

Shares of Nivalis Therapeutics (NASDAQ:NVLS) traded down 54.24% during midday trading on Tuesday, reaching $2.86. The company’s stock had a trading volume of 1,818,249 shares. The firm has a 50-day moving average of $6.46 and a 200-day moving average of $5.84. The stock’s market cap is $44.45 million. Nivalis Therapeutics has a one year low of $2.78 and a one year high of $9.45.

Nivalis Therapeutics (NASDAQ:NVLS) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. On average, analysts forecast that Nivalis Therapeutics will post ($2.10) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Nivalis Therapeutics Inc. (NVLS) Lowered to Market Perform at Raymond James Financial Inc.” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/29/nivalis-therapeutics-inc-nvls-lowered-to-market-perform-at-raymond-james-financial-inc.html.

In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of the company’s stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total value of $46,327.20. Following the completion of the transaction, the executive vice president now owns 18,056 shares in the company, valued at approximately $143,725.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in NVLS. Paloma Partners Management Co acquired a new position in shares of Nivalis Therapeutics during the second quarter worth about $105,000. Bank of New York Mellon Corp increased its position in shares of Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the period. Spark Investment Management LLC acquired a new position in shares of Nivalis Therapeutics during the third quarter worth about $145,000. Endurant Capital Management LP increased its position in shares of Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares during the period. Finally, Opaleye Management Inc. increased its position in shares of Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock worth $1,287,000 after buying an additional 160,000 shares during the period. Hedge funds and other institutional investors own 79.26% of the company’s stock.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Stock Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related stocks with our FREE daily email newsletter.